Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Prothione General Information
Prothione LLC has developed a pro-glutathione therapy in capsule form that demonstrated positive results in a Phase II clinical trial for mild to moderate COVID‑19. The trial showed statistically significant reductions in viral load and time to clinical resolution compared to placebo. The product was safe and well-tolerated. An over-the-counter version called Immune Formulation 200® (IF200) has been approved by the Rwanda FDA and is available for sale in the US[1][3].
Contact Information
Primary Industry
Biotech
Corporate Office
Franklin, Tennessee
United States
United States
Drug Pipeline
prothione
Phase 2Key Partnerships
Planning collaborations for Phase III trials; no major pharma partnerships disclosed[3]
Prothione Funding
No funding data available
To view Prothione's complete valuation and funding history, request access »